AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial
<p><strong>Background:</strong> Dolutegravir has superior efficacy and tolerability than lopinavir-ritonavir in second-line antiretroviral therapy after failure of a first-line non-nucleoside reverse transcriptase inhibitors-based regimen, when dolutegravir is accompanied by at lea...
প্রধান লেখক: | Zhao, Y, Keene, C, Griesel, R, Sayed, K, Gcwabe, Z, Jackson, A, Ngwenya, O, Schutz, C, Goliath, R, Cassidy, T, Goemaere, E, Hill, A, Maartens, G, Meintjes, G |
---|---|
বিন্যাস: | Journal article |
ভাষা: | English |
প্রকাশিত: |
F1000Research
2021
|
অনুরূপ উপাদানগুলি
অনুরূপ উপাদানগুলি
-
AntiRetroviral Therapy In Second-line: investigating Tenofovir-lamivudine-dolutegravir (ARTIST): protocol for a randomised controlled trial [version 1; peer review: 2 approved, 1 approved with reservations]
অনুযায়ী: Zimasa Gcwabe, অন্যান্য
প্রকাশিত: (2021-02-01) -
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen
অনুযায়ী: Keene, CM, অন্যান্য
প্রকাশিত: (2021) -
Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks
অনুযায়ী: Keene, CM, অন্যান্য
প্রকাশিত: (2023) -
Virologic outcomes with tenofovir-lamivudine-dolutegravir in adults failing PI-based second-line ART
অনুযায়ী: Ying Zhao, অন্যান্য
প্রকাশিত: (2024-04-01) -
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
অনুযায়ী: Lisi Deng, অন্যান্য
প্রকাশিত: (2022-01-01)